Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Ángel Guerrero Zotano, Neelima Denduluri, Debra A. Patt, Erhan Gökmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Z. Tomasevic, Katarína Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martín, Arlene Chan